CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy : Results from the ISG-STS 1001 study
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori)
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori)
Chibon, F. (Cancer Research Center of Toulouse (CRCT))
Coindre, J.M. (Institut Bergonié)
Italiano, Antoine (Early Phase Trials and Sarcoma Units. Institut Bergonié)
Romagnosa, Cleofe (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau)
Dei Tos, Angelo (University of Padua School of Medicine)
Braglia, L. (IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia (Itàlia))
Palmerini, E. (IRCCS Istituto Ortopedico Rizzoli)
Quagliuolo, V. (Humanitas Research Hospital (Itàlia))
Broto, J.M. (Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz)
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Grignani, Giovanni (Candiolo Cancer Institute)
Brunello, A. (Istituto Oncologico Veneto)
Blay, J.Y. (UNICANCER & University Lyon I)
Beveridge, R.D. (Hospital Universitari i Politècnic La Fe (València))
Lugowska, Iwona (Instytut im. Marii Sklodowskiej-Curie)
Lesluyes, T. (Cancer Research Center of Toulouse)
Maestro, R. (Centro di Riferimento Oncologico di Aviano IRCCS)
Merlo, F.D. (IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia (Itàlia))
Casali, P.G. (Fondazione IRCCS Istituto Nazionale dei Tumori)
Gronchi, A. (Fondazione IRCCS Istituto Nazionale dei Tumori)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001). Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2). The 10-year overall survival probability (pr-OS) according to SARCULATOR was calculated, and patients were classified accordingly (low-risk, Sarc-LR, 10-year pr-OS>60%; high-risk, Sarc-HR, 10-year pr-OS<60%). Survival functions were estimated using the Kaplan-Meier method and compared using log-rank test. Eighty-six patients were included, 30 C1 and 56 C2, 49 Sarc-LR and 37 Sarc-HR. A low level of agreement between CINSARC and SARCULATOR was observed (Cohen's Kappa = 0. 174). The 5-year relapse-free survival in C1 and C2 were 0. 57 and 0. 55 (p = 0. 481); 5-year metastases-free survival 0. 63 and 0. 64 (p = 0. 740); 5-year OS 0. 80 and 0. 72 (p = 0. 460). The 5-year OS in C1 treated with ST and HT chemotherapy was 0. 84 and 0. 76 (p = 0. 251) respectively; in C2 treated it was 0. 72 and 0. 70 (p = 0. 349). The 5-year OS in Sarc-LR treated with S and HT chemotherapy was 0. 80 and 0. 82 (p = 0. 502) respectively; in Sarc-HR it was 0. 70 and 0. 61 (p = 0. 233). Our results, although constrained by the small size of the series, suggest that CINSARC has weak prognostic power in high-risk, localized STS treated with neoadjuvant chemotherapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	CINSARC ; Chemotherapy ; Outcome ; Prognostication ; Sarcoma
Publicat a:	Cancer Medicine, Vol. 12 Núm. 2 (january 2023) , p. 1350-1357, ISSN 2045-7634

DOI: 10.1002/cam4.5015
PMID: 35848358

8 p, 613.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats